1![SUPPLEMENTARY
INFORMATION:
Specificity
and
mechanism-‐ of-‐action
of
the
JAK2
tyrosine
kinase
inhibitors
ruxolitinib
and
SAR302503
(TG101348)
1. Deter SUPPLEMENTARY
INFORMATION:
Specificity
and
mechanism-‐ of-‐action
of
the
JAK2
tyrosine
kinase
inhibitors
ruxolitinib
and
SAR302503
(TG101348)
1. Deter](https://www.pdfsearch.io/img/b33b06ff4641711416f4f32a5b937960.jpg) | Add to Reading ListSource URL: www.biochem-caflisch.uzh.ch- Date: 2014-03-12 10:03:01
|
---|
2![Myelofibrosis / Janus kinase inhibitor / Splenomegaly / Myeloproliferative neoplasm / Ruxolitinib / Medical diagnosis / Polycythemia vera Myelofibrosis / Janus kinase inhibitor / Splenomegaly / Myeloproliferative neoplasm / Ruxolitinib / Medical diagnosis / Polycythemia vera](/pdf-icon.png) | Add to Reading ListSource URL: www.bcshguidelines.comLanguage: English - Date: 2015-09-20 08:20:56
|
---|
3![Phase 2 trial of PRM-151, an anti-fibrotic agent, in patients with myelofibrosis: Stage 1 results Srdan Verstovsek1, Ruben Mesa2, Lynda Foltz3, Vikas Gupta4, John Mascarenhas5, Ellen Ritchie6, Ronald Hoffman5, Richard Phase 2 trial of PRM-151, an anti-fibrotic agent, in patients with myelofibrosis: Stage 1 results Srdan Verstovsek1, Ruben Mesa2, Lynda Foltz3, Vikas Gupta4, John Mascarenhas5, Ellen Ritchie6, Ronald Hoffman5, Richard](https://www.pdfsearch.io/img/6478b55422631656af8fae0f81bdcf6d.jpg) | Add to Reading ListSource URL: www.promedior.comLanguage: English - Date: 2015-02-08 17:25:15
|
---|
4![Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval, Quebec Canada H9S 1A9 www.novartis.ca Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval, Quebec Canada H9S 1A9 www.novartis.ca](https://www.pdfsearch.io/img/78414298a37a920cf1bd331896515f57.jpg) | Add to Reading ListSource URL: www.novartis.caLanguage: English - Date: 2015-05-13 10:22:06
|
---|
5![](https://www.pdfsearch.io/img/abfb10742ddfb9185753cd5055cfd03b.jpg) | Add to Reading ListSource URL: www.pbs.gov.auLanguage: English - Date: 2014-10-01 21:56:24
|
---|
6![Statement of Advice ruxolitinib (Jakavi®) 5mg, 15mg and 20mg Tablets Novartis Pharmaceuticals UK Ltd (No: 867/13) Statement of Advice ruxolitinib (Jakavi®) 5mg, 15mg and 20mg Tablets Novartis Pharmaceuticals UK Ltd (No: 867/13)](https://www.pdfsearch.io/img/c242ed625ffb755296d74a78e4ee2829.jpg) | Add to Reading ListSource URL: www.scottishmedicines.org.ukLanguage: English |
---|
7![PBAC STAKEHOLDER MEETING OUTCOME STATEMENT RUXOLITINIB FOR MYELOFIBROSIS 22 September 2014 The Sheraton Hotel, Melbourne Attendees Members of the Pharmaceutical Benefits Advisory Committee (PBAC), the consumer PBAC STAKEHOLDER MEETING OUTCOME STATEMENT RUXOLITINIB FOR MYELOFIBROSIS 22 September 2014 The Sheraton Hotel, Melbourne Attendees Members of the Pharmaceutical Benefits Advisory Committee (PBAC), the consumer](https://www.pdfsearch.io/img/83d9c59fdc854db4cefdc61bb2699148.jpg) | Add to Reading ListSource URL: pbs.gov.auLanguage: English - Date: 2015-03-12 23:53:04
|
---|
8![Pharmaceutical Benefits Scheme / Pharmacology / Myelofibrosis / International Prognostic Scoring System / IPSS / Clinical trial / Medicine / Health / Ruxolitinib Pharmaceutical Benefits Scheme / Pharmacology / Myelofibrosis / International Prognostic Scoring System / IPSS / Clinical trial / Medicine / Health / Ruxolitinib](/pdf-icon.png) | Add to Reading ListSource URL: pbs.gov.auLanguage: English - Date: 2015-03-12 23:53:04
|
---|
9![Pharmacology / Medicine / Healthcare in Australia / Pharmaceutical Benefits Scheme / Pharmaceuticals policy / Health / Ruxolitinib / Infliximab / Ustekinumab / Immunosuppressants / Centocor / Monoclonal antibodies Pharmacology / Medicine / Healthcare in Australia / Pharmaceutical Benefits Scheme / Pharmaceuticals policy / Health / Ruxolitinib / Infliximab / Ustekinumab / Immunosuppressants / Centocor / Monoclonal antibodies](/pdf-icon.png) | Add to Reading ListSource URL: www.pbs.gov.auLanguage: English - Date: 2015-01-19 17:21:09
|
---|
10![ruxolitinib (as phosphate), 5mg, 15mg, & 20mg tablets (Jakavi®) SMC No[removed]Novartis Pharmaceuticals UK Ltd. 06 February 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above produc ruxolitinib (as phosphate), 5mg, 15mg, & 20mg tablets (Jakavi®) SMC No[removed]Novartis Pharmaceuticals UK Ltd. 06 February 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above produc](https://www.pdfsearch.io/img/45933adfb852053533bdad6d50a66202.jpg) | Add to Reading ListSource URL: www.scottishmedicines.org.ukLanguage: English |
---|